Can-Fite BioPharma Ltd.
Calidad de datos: 100%
CANF
NYSE
Manufacturing
Chemicals
$2.92
▼
$0.01
(-0.34%)
Cap. Mercado: 6.85 M
Precio
$2.92
Cap. Mercado
6.85 M
Rango del Día
—
Rango de 52 Semanas
—
Volumen
—
Apertura —
Promedio 50D / 200D
—
Promedio 50D / 200D
—
Quick Summary
Puntos Clave
Revenue declined -16.99% annually over 5 years
Negative free cash flow of -8.95 M
Revenue growth is decelerating — 1Y growth trails 5Y average by 22.92%
Capital efficient — spends only 0.49% of revenue on capex
Crecimiento
Revenue Growth (5Y)
-16.99%
Below sector avg (1.82%)
Revenue (1Y)-39.91%
Earnings (1Y)N/A
FCF Growth (3Y)N/A
Calidad
Return on Equity
-295.00%
Below sector avg (-53.53%)
ROIC-164.88%
Net Margin-2426.67%
Op. Margin-2456.79%
Seguridad
Debt / Equity
N/A
Current Ratio3.60
Interest Coverage-35.04
Valoración
PE (TTM)
-0.70
Above sector avg (-1.48)
P/B Ratio1.64
EV/EBITDAN/A
Dividend YieldN/A
Historial de Precios
Tendencias Financieras
Comparación con Pares
vs mediana del sector Manufacturing (1366 pares)
Comparación con Pares
vs mediana del sector Manufacturing (1366 pares)| Métrica | Acción | Mediana del Sector |
|---|---|---|
| P/E | -0.7 | -1.5 |
| P/B | 1.6 | 1.6 |
| ROE % | -295.0 | -53.5 |
| Net Margin % | -2426.7 | -41.5 |
| Rev Growth 5Y % | -17.0 | 1.8 |
| D/E | — | 0.3 |
Precio Objetivo de Analistas
1 analista
Buy
Actual
$2.92
Objetivo
$50.00
$50.00
$50.00
$50.00
Pronóstico
EPS Futuro
-$1.04
Ingresos Est.
1.41 M
Estimaciones de Ganancias
| Período | EPS Est. | Ingresos Est. | Analistas |
|---|---|---|---|
| FY2027 |
-$1.04
-$1.04 – -$1.04
|
1.41 M | 1 |
| FY2026 |
-$1.97
-$1.97 – -$1.97
|
0.0 | 1 |
| Período | EPS Est. | Ingresos Est. | Analistas |
|---|---|---|---|
| 2026 Q2 |
-$0.51
-$0.51 – -$0.51
|
0.0 | 1 |
| 2026 Q1 |
-$1.43
-$1.43 – -$1.43
|
0.0 | 1 |
Sorpresas de Ganancias
Últimos 4 trimestres
| Trimestre | EPS Est. | EPS Real | Sorpresa |
|---|---|---|---|
| Q42025 | -$2.80 | N/A | — |
| Q32025 | -$2.80 | N/A | — |
| Q22025 | -$2.40 | $0.00 | +100.0% |
| Q12025 | -$2.40 | N/A | — |
All Fundamental Metrics
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | -39.91% | Revenue Growth (3Y) | N/A |
| Earnings Growth (1Y) | N/A | Earnings Growth (3Y) | N/A |
| Revenue Growth (5Y) | -16.99% | Earnings Growth (5Y) | N/A |
| Profitability | |||
| Revenue (TTM) | 405,000.0 | Net Income (TTM) | -9.83 M |
| ROE | -295.00% | ROA | -144.08% |
| Gross Margin | N/A | Operating Margin | -2456.79% |
| Net Margin | -2426.67% | Free Cash Flow (TTM) | -8.95 M |
| ROIC | -164.88% | FCF Growth (3Y) | N/A |
| Safety | |||
| Debt / Equity | N/A | Current Ratio | 3.60 |
| Interest Coverage | -35.04 | Asset Turnover | 0.06 |
| Working Capital | 5.50 M | Tangible Book Value | 4.18 M |
| Dividends | |||
| Dividend Yield | N/A | Payout Ratio | N/A |
| Dividend Growth (3Y) | N/A | Dividend Growth (5Y) | N/A |
| Consecutive Div Years | N/A | ||
| Valuation | |||
| P/E Ratio | -0.70 | Forward P/E | N/A |
| P/B Ratio | 1.64 | P/S Ratio | 16.92 |
| PEG Ratio | N/A | Forward PEG | N/A |
| EV/EBITDA | N/A | Fwd EV/EBITDA | N/A |
| Forward P/S | 4.87 | Fwd Earnings Yield | N/A |
| FCF Yield | -130.63% | ||
| Market Cap | 6.85 M | Enterprise Value | 398,233.0 |
| Per Share | |||
| EPS (Diluted TTM) | -5.97 | Revenue / Share | 0.17 |
| FCF / Share | -3.81 | OCF / Share | -3.81 |
| EPS CAGR (1Y) | N/A | EPS CAGR (5Y) | N/A |
| EPS CAGR (10Y) | N/A | ||
| Efficiency | |||
| CapEx / Revenue | 0.49% | FCF Conversion | 91.08% |
| SBC-Adj. FCF | -9.63 M | Growth Momentum | -22.92 |
Income Statement
Annual, most recent first
Income Statement
Annual, most recent first| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 405,000.0 | 674,000.0 | — | 810,000.0 | 853,000.0 |
| Net Income | -9.83 M | -7.88 M | -7.63 M | -10.17 M | -12.62 M |
| EPS (Diluted) | -5.97 | 0.00 | -0.01 | -0.01 | — |
| Gross Profit | — | — | — | — | — |
| Operating Income | -9.95 M | -8.13 M | -8.20 M | -10.10 M | -12.84 M |
| EBITDA | — | — | — | — | — |
| R&D Expenses | 6.69 M | 5.76 M | 5.98 M | 7.76 M | 9.85 M |
| SG&A Expenses | — | — | — | 263,000.0 | — |
| D&A | 24,000.0 | — | — | 14,000.0 | 14,000.0 |
| Interest Expense | 284,000.0 | -291,000.0 | — | -77,000.0 | 227,000.0 |
| Income Tax | — | — | — | — | — |
Balance Sheet
Annual, most recent first
Balance Sheet
Annual, most recent first| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 9.51 M | 9.12 M | 9.99 M | 9.28 M | 20.25 M |
| Total Liabilities | — | — | — | — | — |
| Shareholders' Equity | 5.59 M | 5.44 M | 6.24 M | 4.47 M | 14.38 M |
| Total Debt | — | — | — | — | — |
| Cash & Equivalents | 5.53 M | 4.83 M | 4.28 M | 2.98 M | 4.39 M |
| Current Assets | 9.44 M | 8.98 M | 9.91 M | 9.16 M | 20.07 M |
| Current Liabilities | 2.73 M | 2.05 M | 2.02 M | 2.50 M | 2.73 M |
{"event":"ticker_viewed","properties":{"ticker":"CANF","listing_kind":"stock","pathname":"/stocks/canf","exchange":"NYSE","country":"US"}}




